Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duobrii vs Clobetasol in Psoriasis
NCT06042647Phase 4Completed
- Sponsor
- Dermatology Consulting Services
- Start
- Jul 2023
- Primary completion
- Nov 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of halobetasol propionate + tazarotene in plaque psoriasis (2 arms), sponsored by Dermatology Consulting Services. Primary endpoint: Concentration of TNF-a and IL-17A in Psoriatic Plaques at 8 weeks. Started Jul 2023; status: completed.
02
Drugs
halobetasol propionate + tazarotene
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06042647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06042647.